Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Buys 6,146 Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. bought 6,146 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was bought at an average cost of $24.89 per share, for a total transaction of $152,973.94. Following the completion of the transaction, the insider directly owned 6,383,114 shares of the company’s stock, valued at approximately $158,875,707.46. The trade was a 0.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. bought 61,523 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.98 per share, for a total transaction of $1,536,844.54.
• On Wednesday, May 20th, Ra Capital Management, L.P. bought 996 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 19th, Ra Capital Management, L.P. bought 3,802 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.97 per share, for a total transaction of $94,935.94.
• On Tuesday, May 12th, Ra Capital Management, L.P. bought 6,387 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. bought 39,869 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. bought 1,483 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Up 3.7%

COAG stock traded up $0.94 during midday trading on Wednesday, reaching $26.45. 372,565 shares of the company’s stock traded hands, compared to its average volume of 221,371. Hemab Therapeutics Holdings, Inc. has a fifty-two week low of $23.00 and a fifty-two week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Analyst Ratings Changes

COAG has been the topic of a number of recent research reports. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Evercore initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. HC Wainwright initiated coverage on shares of Hemab Therapeutics in a research report on Wednesday. They set a “buy” rating and a $40.00 price target on the stock. Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.40.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.